Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Note 5 - Licences, Royalty Collaborative and Contractual Arrangements (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended	3 Months Ended		15 Months Ended			1 Months Ended	30 Months Ended
	Mar. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Major Countries GSK	Sep. 30, 2013 Australia, New Zealand, South Africa and Indonesia GSK	Sep. 30, 2013 Daiichi Sankyo	Mar. 31, 2011 BARDA	Sep. 30, 2013 BARDA
Note 5 - Licences, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage				7.00%	10.00%	4.00%
Contracts Revenue (in Dollars)	$ 231.2	$ 0.1	$ 0.2					$ 38.6
Contract Term							5 years